Cargando…

Are we ready to design oral PROTACs®?

PROTACs® are expected to strongly impact the future of drug discovery. Therefore, in this work we firstly performed a statistical study to highlight the distribution of E3 ligases and POIs collected in PROTAC-DB, the main online database focused on degraders. Moreover, since the emerging technology...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jimenez, Diego Garcia, Sebastiano, Matteo Rossi, Caron, Giulia, Ermondi, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Association of Physical Chemists 2021
Materias:	Original Scientific Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920102/ https://www.ncbi.nlm.nih.gov/pubmed/35300370 http://dx.doi.org/10.5599/admet.1037

Ejemplares similares

Rational Control of Molecular Properties Is Mandatory to Exploit the Potential of PROTACs as Oral Drugs
por: Ermondi, Giuseppe, et al.
Publicado: (2021)

Designing Soluble PROTACs: Strategies and Preliminary Guidelines
por: García Jiménez, Diego, et al.
Publicado: (2022)

The Quest for Oral PROTAC drugs: Evaluating the Weaknesses of the Screening Pipeline
por: Apprato, Giulia, et al.
Publicado: (2023)

PROTACs and Building Blocks: The 2D Chemical Space in Very Early Drug Discovery
por: Ermondi, Giuseppe, et al.
Publicado: (2021)

Solubility prediction in the bRo5 chemical space: where are we right now?
por: Ermondi, Giuseppe, et al.
Publicado: (2020)

Chamelogk: A Chromatographic Chameleonicity Quantifier to Design Orally Bioavailable Beyond-Rule-of-5 Drugs
por: Garcia Jimenez, Diego, et al.
Publicado: (2023)

In Silico Tools to Extract the Drug Design Information Content of Degradation Data: The Case of PROTACs Targeting the Androgen Receptor
por: Apprato, Giulia, et al.
Publicado: (2023)

Refinement of Computational Access to Molecular Physicochemical Properties: From Ro5 to bRo5
por: Rossi Sebastiano, Matteo, et al.
Publicado: (2022)

Conformational Sampling Deciphers the Chameleonic Properties of a VHL-Based Degrader
por: Ermondi, Giuseppe, et al.
Publicado: (2023)

Personalized Treatment for Infantile Ascending Hereditary Spastic Paralysis Based on In Silico Strategies
por: Rossi Sebastiano, Matteo, et al.
Publicado: (2022)

Clinical considerations for the design of PROTACs in cancer
por: Nieto-Jiménez, Cristina, et al.
Publicado: (2022)

Modeling ErbB2-p130Cas interaction to design new potential anticancer agents
por: Costamagna, Andrea, et al.
Publicado: (2019)

Author Correction: Modeling ErbB2-p130Cas interaction to design new potential anticancer agents
por: Costamagna, Andrea, et al.
Publicado: (2019)

Impact of COVID-19 pandemic on hepatitis C elimination from the clinical microbiologist perspective. Are we ready?()
por: Aguilera, Antonio, et al.
Publicado: (2021)

Design, synthesis, and biological evaluation of potent FAK-degrading PROTACs
por: Qin, Qiaohua, et al.
Publicado: (2022)

PROTAC-DB: an online database of PROTACs
por: Weng, Gaoqi, et al.
Publicado: (2020)

Managing Experimental 3D Structures in the Beyond‐Rule‐of‐5 Chemical Space: The Case of Rifampicin
por: Ermondi, Giuseppe, et al.
Publicado: (2021)

Design and Characterization of SGK3-PROTAC1, an Isoform Specific SGK3 Kinase PROTAC Degrader
por: Tovell, Hannah, et al.
Publicado: (2019)

Estrogen Receptor-α Targeting: PROTACs, SNIPERs, Peptide-PROTACs, Antibody Conjugated PROTACs and SNIPERs
por: Negi, Arvind, et al.
Publicado: (2022)

Structure‐Based Design of a Macrocyclic PROTAC
por: Testa, Andrea, et al.
Publicado: (2019)

Novel approaches for the rational design of PROTAC linkers
por: Zagidullin, Almaz, et al.
Publicado: (2020)

PROTAC-DB 2.0: an updated database of PROTACs
por: Weng, Gaoqi, et al.
Publicado: (2022)

Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope
por: Ma, Sinan, et al.
Publicado: (2022)

Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression
por: Chen, Si, et al.
Publicado: (2022)

Physicochemical Property Determinants of Oral Absorption for PROTAC Protein Degraders
por: Hornberger, Keith R., et al.
Publicado: (2023)

PROTACs in gastrointestinal cancers
por: Chen, Yu, et al.
Publicado: (2022)

PROTACs for BRDs proteins in cancer therapy: a review
por: Wang, Chao, et al.
Publicado: (2022)

DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs
por: Li, Fenglei, et al.
Publicado: (2022)

Current strategies for the design of PROTAC linkers: a critical review
por: Troup, Robert I., et al.
Publicado: (2020)

Solubility Enhanced Formulation Approaches to Overcome Oral Delivery Obstacles of PROTACs
por: Pöstges, Florian, et al.
Publicado: (2023)

Are we ready?()
por: Pedrosa, C.
Publicado: (2020)

Are we ready for the ERAS protocol in colorectal surgery?
por: Kisielewski, Michał, et al.
Publicado: (2017)

Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation
por: Jiang, Liang, et al.
Publicado: (2021)

Conformational Sampling of Macrocyclic Drugs in Different Environments: Can We Find the Relevant Conformations?
por: Poongavanam, Vasanthanathan, et al.
Publicado: (2018)

Rational Design and Synthesis of HSF1-PROTACs for Anticancer Drug Development
por: Sharma, Chiranjeev, et al.
Publicado: (2022)

The PROTAC technology in drug development
por: Zou, Yutian, et al.
Publicado: (2019)

PROTACs: The Future of Leukemia Therapeutics
por: Anwar, Zubair, et al.
Publicado: (2022)

PROTACs in the Management of Prostate Cancer
por: Yedla, Poornachandra, et al.
Publicado: (2023)

Listeria monocytogenes contamination of ready‐to‐eat foods and the risk for human health in the EU
por: Ricci, Antonia, et al.
Publicado: (2018)

Light-mediated multi-target protein degradation using arylazopyrazole photoswitchable PROTACs (AP-PROTACs)
por: Zhang, Qisi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sa1v1aud8o3u5cbkurkglmb32s